The ICON Cares 2025 Report is now live. Sharing progress across clinical research people, communities and ESG priorities. Read more: ow.ly/WHo650ZF35Q #ICONCares #ESG #ClinicalResearch #Sustainability #SDG3

Meet ICON’s hepatology experts at #AASLD26 to discuss how our experience across hepatology, MASH and obesity can help you navigate clinical development, from trial design and patient identification to study execution. Arrange a meeting: ow.ly/mgJa50ZZiVU

Building an AI-enabled medical device? A focused FDA Pre-Sub can help reduce uncertainty, strengthen your regulatory strategy and avoid costly delays. Read our latest blog: ow.ly/xbWp50ZYlUF #AI #SaMD #DigitalHealth #FDA

Current preclinical models are imperfect predictors of human immunity, making clinical translation the single largest obstacle for gonorrhoea vaccine candidates. Incorporating patient-reported outcomes will be essential to proving meaningful efficacy. ow.ly/jWoZ50ZUQ8I

Rare disease feasibility starts with understanding where patients receive care and barrier to participation. Meet ICON at #WorldOrphanEU, booth 313 to discuss targeted site identification and patient-centred study delivery. Arrange a meeting: ow.ly/Kt5h50ZQ1Xk

Europe’s #oncology biosimilar market is entering its next phase. As science and regulation evolve, developers must connect evidence generation with manufacturing, market access and commercial planning. Read the blog: ow.ly/AYlQ50ZZhTN #ESMO26 #ESMOmeetings #Biosimilars

As regulatory pathways evolve, biosimilar sponsors may have new opportunities to streamline development through stronger analytical evidence. Read more: ow.ly/XpfT50ZVfb0 #Biosimilars #RegulatoryAffairs #LifeSciences #Biotech

Meet scientific publication security and compliance with increased confidence. PubsHub PMSolution features audit trail support for GPP2022 and ICMJE guidelines to meet best practices. Ask for your demo: ow.ly/97gH50ZEosa

FDA Pre-Subs remain one of the most effective ways to reduce uncertainty for AI-enabled SaMD programmes. Our latest whitepaper explores best practices, common pitfalls and key considerations for successful regulatory engagement. Download now: ow.ly/9L3X50ZypAY #FDA #SaMD

What's next for evidence generation? Join us at booth #1615 during #ISPOREurope2026 to explore new research from ICON and Mapi Research Trust and discuss the evolving evidence landscape. ow.ly/8n9j50ZUkOv #ISPOR #HEOR #PatientOutcomes

Oncology delivery starts with informed feasibility and the right site strategy. Meet ICON at #ESMO26, booth #8005, to discuss site access, patient recruitment and study delivery. Connect with our team at ESMO: ow.ly/kIFl50ZTnYx

Use the time before the clock starts The final JCA scope can leave developers roughly three months to submit a dossier. Evidence searches, subgroup analyses and indirect comparisons must be planned much earlier. ow.ly/x2hS50ZYmhl

Immunotherapies originally developed for cancer may benefit many patients with chronic disease. Read more to find out how different categories of immunotherapy, including CAR therapies, T cell engagers and ICIs, are being applied to new indications. ow.ly/yF5i50ZTuE0

Q: When should key COA decisions be made? A: Before the endpoint is locked. Learn how early #COA selection & development decisions can strengthen evidence, reduce risk + support regulatory strategy. Register for the webinar now: ow.ly/U4k950ZIEu8

How hard do you work to choose the right research publishing platform? Probably too hard. We can make it easier for you. PubsHub Journals and Congresses has information on over 10,000 entries with over 50 fields of data for each. Take a demo. ow.ly/S2Il50ZEopz

You've got 60 minutes with the FDA. Will you spend it answering questions or getting answers? Learn how AI-enabled #SaMD developers can prepare for a more productive FDA Pre-Sub meeting. ow.ly/hNPh50ZYlPe #AI #FDA #MedTech

Where can AI provide practical value in oncology development? Meet ICON at #ESMO26, booth #8005, to discuss applications across biomarkers, patient selection, trial design and evidence generation. Schedule a meeting: ow.ly/cTxf50ZTnYa

Approval does not guarantee reimbursement EMA marketing authorisation does not guarantee reimbursement. JCA evidence must address relative clinical effectiveness, safety and patient-relevant outcomes for European decision-making. ow.ly/Kn9A50ZYmcR

For drug developers advancing immunotherapies into chronic diseases, understanding the unique needs of different patient populations is essential. Explore key considerations across autoimmune disease, cardiometabolic conditions, and women’s health. ow.ly/Tmvv50ZTuAJ

Heading to Boston for The MedTech Conference? Meet ICON's MDDR team to discuss strategies for devices, diagnostics, wearables, digital health technologies and combination products, from development through post-market evidence generation. ow.ly/JQjI50ZLxAU #MTC26

Drop by booth #69 at #OCTNewEngland2026, 27– 28 October. Meet the ICON team to explore new solutions to common issues within clinical trials. ow.ly/SXsm50ZTpKJ